Objective: The MiniMed™ 780G system with the adjunctive Guardian™ sensor 3 that requires calibration has been commercially available in Europe, since October 2020. Since October 2021, the system has been available with the non-adjunctive Guardian™ 4 sensor, which does not require calibration. In this study, glycemic outcomes during real-world MiniMed™ 780G system use with both sensors were evaluated.

Methods: Analyses were based on data collected on Dec 10, 2021, from consenting system users (N=674) residing in Europe with ≥days of sensor glucose (SG) data from both sensors. Glycemic outcomes including mean±SD of the glucose management indicator (GMI) and percentage of time spent in target range of 70-180mg/dL (TIR) , at <54mg/dL and <70mg/dL (TBR) and at >180mg/dL (TAR) were assessed. The time spent in AHCL, number of AHCL exits/week and self-monitoring of blood glucose (SMBG) measurements/day were also determined. Results:

System use with the Guardian™ 4 sensor versus Guardian™ sensor 3 demonstrated 94±9% vs 93±11% of time in AHCL, 73.1±11.4% vs 74.6±9.8% TIR, 0.11±0.16% vs 0.51±0.58% TBR<54, 1.6±1.4% vs 2.4±1.8% TBR<70, and 25.3±11.7% vs 23.1±10.0% TAR<180. During the night (12AM-6AM) , greater glycemic control was observed: with 81.6±13.3% vs 82.8±11.0% TIR, 0.09±0.22% vs 0.42±0.69% TBR<54, 1.1±1.5% vs 1.8±1.9% TBR<70 and 17.3±13.3% vs 15.4±11.0% TAR>180. The GMI was 6.98±0.43% vs 6.84±0.38%. Closed-loop exits were 0.83±1.02 vs 1.1±1.06/week and SMBG measurements were 0.9±0.9 vs 3.3±0.9/day. Conclusion: Real-world MiniMed™ 780G system use findings indicate reduced burden related to SMBG measurements and closed-loop exits, with the Guardian™ 4 sensor, while maintaining favorable glycemic outcomes of the MiniMed™ 780G + Guardian™ sensor 3 system.


R.A. Vigersky: Employee; Medtronic. J. Castañeda: Employee; Medtronic. A. Arrieta: Employee; Medtronic. T.L. Cordero: Employee; Medtronic, Medtronic. A.S. Rhinehart: Employee; Medtronic. Stock/Shareholder; Medtronic. J. Shin: Employee; Medtronic.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.